Kamada shares climbed after the company released its guidance for 2025 and updated its progress on a therapy trial. The biopharmaceutical company's stock advanced 16% to $7.92. Shares have gained ...

Earlier results from a short 28-day study showed promising weight loss outcomes with good tolerability, supporting the potential success of the ongoing trial ... a positive outlook for Viking ...